Journal of Cancer Research and Clinical Oncology

, Volume 134, Issue 12, pp 1363–1369

Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma

  • Yasuo Awakura
  • Eijiro Nakamura
  • Takeshi Takahashi
  • Hirokazu Kotani
  • Yoshiki Mikami
  • Tadashi Kadowaki
  • Akira Myoumoto
  • Hideo Akiyama
  • Noriyuki Ito
  • Toshiyuki Kamoto
  • Toshiaki Manabe
  • Hitoshi Nobumasa
  • Gozoh Tsujimoto
  • Osamu Ogawa
Original Paper

Abstract

Purpose

Renal cell carcinoma (RCC) is characterized by a variable and unpredictable clinical course. Thus, accurate prediction of the prognosis is important in clinical settings. We conducted microarray-based study to identify a novel prognostic marker in conventional RCC.

Patients and methods

The present study included the patients surgically treated at Kyoto University Hospital. Gene expression profiling of 39 samples was carried out to select candidate prognostic markers. Quantitative real-time PCR of 65 samples confirmed the microarray experiment results. Finally, we evaluated the significance of potential markers at their protein expression level by immunohistochemically analyzing 230 conventional RCC patients.

Results

Using expression profiling analysis, we identified 14 candidate genes whose expression levels predicted unfavorable disease-specific survival. Next, we examined the expression levels of nine candidate genes by quantitative real-time PCR and selected CUB-domain containing protein 1 (CDCP1) for further immunohistochemical analysis. Positive staining for CDCP1 inversely correlated with disease-specific and recurrence-free survivals. In multivariate analysis including clinical/pathological factors, CDCP1 staining was a significant predictor of disease-specific and recurrence-free survivals.

Conclusions

We identified CDCP1 as a potential prognostic marker for conventional RCC. Further studies might be required to confirm the prognostic value of CDCP1 and to understand its function in RCC progression.

Keywords

CDCP1 Microarray Prognosis Renal cell carcinoma 

Supplementary material

432_2008_412_MOESM1_ESM.tif (55 kb)
Fig. 1S. Survival curves for patients with conventional RCC in relation to the expression of 9 candidate genes. CDCP1 expression was significantly associated with prognosis (shown in the rounded rectangle) (TIFF 55 kb)
432_2008_412_MOESM2_ESM.xls (15 kb)
Table 1S. The sequences of primers used in the present study (XLS 15 kb)
432_2008_412_MOESM3_ESM.xls (18 kb)
Table 2S. Genes whose expression levels correlate with unfavorable prognosis in microarray experiment (XLS 17 kb)
432_2008_412_MOESM4_ESM.doc (24 kb)
Supplementary materials and methods (DOC 23 kb)

References

  1. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24:5333–5343PubMedCrossRefGoogle Scholar
  2. Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489–2498PubMedCrossRefGoogle Scholar
  3. Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR (2002) Post-analysis follow-up and validation of microarray experiments. Nat Genet 32(Suppl):509–514PubMedCrossRefGoogle Scholar
  4. Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271PubMedCrossRefGoogle Scholar
  5. Goldstein NS (1999) Grading of renal cell carcinoma. Urol Clin North Am 26:637–642PubMedCrossRefGoogle Scholar
  6. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22:1783–1794PubMedCrossRefGoogle Scholar
  7. Ihaka R, Gentlaman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299–314CrossRefGoogle Scholar
  8. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T, Aozasa K (2006) Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210:75–84PubMedCrossRefGoogle Scholar
  9. Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF (2006) Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14:65–72PubMedCrossRefGoogle Scholar
  10. Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11:5730–5739PubMedCrossRefGoogle Scholar
  11. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173:1496–1501PubMedCrossRefGoogle Scholar
  12. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11:5128–5139PubMedCrossRefGoogle Scholar
  13. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853–1862PubMedCrossRefGoogle Scholar
  14. Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T, Takahashi K, Tomita Y (2006) Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 95:1244–1249PubMedCrossRefGoogle Scholar
  15. Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169:821–827PubMedCrossRefGoogle Scholar
  16. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163:408–417PubMedCrossRefGoogle Scholar
  17. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103–3111PubMedCrossRefGoogle Scholar
  18. Nentwich HA, Mustafa Z, Rugg MS, Marsden BD, Cordell MR, Mahoney DJ, Jenkins SC, Dowling B, Fries E, Milner CM, Loughlin J, Day AJ (2002) A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module. Chromosomal localization, frequency analysis, modeling, and expression. J Biol Chem 277:15354–15362PubMedCrossRefGoogle Scholar
  19. Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20:4402–4408PubMedCrossRefGoogle Scholar
  20. Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA (1996) Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 14:250–255PubMedGoogle Scholar
  21. Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H (2006) Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. Oncol Rep 15:1181–1184PubMedGoogle Scholar
  22. Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:2323–2333PubMedCrossRefGoogle Scholar
  23. Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Fuzesi L, Poustka A (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11:646–655PubMedGoogle Scholar
  24. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754–9759PubMedCrossRefGoogle Scholar
  25. Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, Merino M, Walther MM, Simon R, Klausner RD, Linehan WM (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100:6958–6963PubMedCrossRefGoogle Scholar
  26. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480PubMedCrossRefGoogle Scholar
  27. Yonezawa Y, Nagashima Y, Sato H, Virgona N, Fukumoto K, Shirai S, Hagiwara H, Seki T, Ariga T, Senba H, Suzuki K, Asano R, Hagiwara K, Yano T (2005) Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinog 43:188–197PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Yasuo Awakura
    • 1
  • Eijiro Nakamura
    • 1
  • Takeshi Takahashi
    • 1
  • Hirokazu Kotani
    • 2
  • Yoshiki Mikami
    • 2
  • Tadashi Kadowaki
    • 3
  • Akira Myoumoto
    • 4
  • Hideo Akiyama
    • 4
  • Noriyuki Ito
    • 1
  • Toshiyuki Kamoto
    • 1
  • Toshiaki Manabe
    • 2
  • Hitoshi Nobumasa
    • 4
  • Gozoh Tsujimoto
    • 3
  • Osamu Ogawa
    • 1
  1. 1.Department of UrologyKyoto University Graduate School of MedicineKyotoJapan
  2. 2.Laboratory of Anatomic PathologyKyoto University HospitalKyotoJapan
  3. 3.Department of Genomic Drug Discovery ScienceKyoto University Graduate School of Pharmaceutical SciencesKyotoJapan
  4. 4.New Frontiers Research LaboratoriesToray Indutries Inc.KamakuraJapan

Personalised recommendations